Therapy Detail

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Filter rows:

Showing 1 to 1 of 1 entries

Drug Name	Trade Name	Synonyms	Drug Classes	Drug Description
Adavosertib		MK-1775\|AZD1775\|AZ1775\|MK1775	WEE1 Inhibitor 8	Adavosertib (MK-1775) is a small molecule inhibitor of the tyrosine kinase WEE1 with potential antineoplastic sensitizing activity (PMID: 22084170, PMID: 32611648).

Showing 1 to 1 of 1 entries

Filter rows:

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Filter rows:

Showing 1 to 16 of 16 entries

Molecular Profile	Indication/Tumor Type	Response Type	Therapy Name	Approval Status	Evidence Type	Efficacy Evidence	References
NRAS mut TP53 mut	colorectal cancer	no benefit	Adavosertib	Phase II	Actionable	In a Phase II trial (FOCUS4-C), Adavosertib (AZD1775) treatment was well-tolerated and resulted in an advantage in progression-free survival (PFS, HR 0.40, p=0.0051) but not overall survival (0.92, p=0.93) compared to active monitoring in patients with metastatic colorectal cancer harboring both RAS and TP53 mutations, however, patients with NRAS mutations or KRAS non-G12/G13 mutations did not benefit from Adavosertib (AZD1775) treatment in subgroup PFS analysis (PMID: 34538072).	34538072
TP53 mutant	Advanced Solid Tumor	predicted - sensitive	Adavosertib	Phase I	Actionable	In a Phase I trial, Adavosertib (MK-1775) treatment resulted in a prtial response in 3 and progressive disease in 2 of 6 patients with advanced solid tumors harboring TP53 mutations (J Clin Oncol 38: 2020 (suppl; abstr 3624); NCT01748825).	detail...
TP53 mutant	Advanced Solid Tumor	predicted - sensitive	Adavosertib	Phase I	Actionable	In a retrospective analysis of a Phase I trial, Adavosertib (MK-1775) combined with a chemotherapy resulted in a 21% (4/19) response rate in advanced solid tumor patients harboring a TP53 mutation and in those without a TP53 mutation, a 12% (4/33) response rate was observed (PMID: 27601554; NCT00648648).	27601554
TP53 mutant	ovarian carcinoma	predicted - sensitive	Adavosertib	Case Reports/Case Series	Actionable	In a Phase I trial, Adavosertib (MK-1775) treatment resulted in a partial response (PR) in 17% (6/35) of patients with advanced solid tumors, 4 of the patients achieved PR had ovarian carcinoma (OVC), and TP53 mutations were identified in 2 of the OVC patients with biopsies available for genomic analysis (J Clin Oncol 38: 2020 (suppl; abstr 3624); NCT01748825).	detail...
TP53 mutant	endometrial carcinoma	predicted - sensitive	Adavosertib	Case Reports/Case Series	Actionable	In a Phase I trial, Adavosertib (MK-1775) treatment resulted in a partial response (PR) in 17% (6/35) of patients with advanced solid tumors, 2 of the patients achieved PR had endometrial carcinoma (EC), and TP53 mutations were identified in 1 of the EC patients with biopsy available for genomic analysis (J Clin Oncol 38: 2020 (suppl; abstr 3624); NCT01748825).	detail...
TP53 mutant	glioblastoma	sensitive	Adavosertib	Preclinical - Pdx	Actionable	In a preclinical study, treatment with Adavosertib (MK-1775) decreased CDK1 phosphorylation and reduced tumor growth in patient-derived xenograft models of glioblastoma multiforme that harbor TP53 mutations (PMID: 27196784).	27196784
ATRX del	hepatocellular carcinoma	sensitive	Adavosertib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Adavosertib (MK-1775) treatment resulted in cell cycle arrest, DNA damage, and apoptosis in hepatocellular carcinoma cell lines with ATRX gene knocked out via CRISPR-Cas9 in culture, and inhibited tumor growth in cell line xenograft models (PMID: 31551363).	31551363
KIT exon 11 del	gastrointestinal stromal tumor	no benefit	Adavosertib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Adavosertib (MK-1775) treatment resulted in reduced cell viability of gastrointestinal stromal tumor cells harboring a KIT exon 11 deletion in culture, but did not lead to improved tumor growth inhibition or prolonged survival compared to controls in cell line xenograft models (PMID: 33320833).	33320833
TP53 mutant	esophagus adenocarcinoma	predicted - sensitive	Adavosertib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Adavosertib (MK-1775) treatment inhibited phosphorylation of Wee1 and Cdk1, and reduced viability of TP53-mutant esophageal adenocarcinoma cells in culture, and led to partial tumor growth delay in cell line xenograft models (PMID: 32220892).	32220892
ATRX R781*	high grade glioma	sensitive	Adavosertib	Preclinical - Patient cell culture	Actionable	In a preclinical study, Adavosertib (MK-1775) inhibited growth of patient-derived glioma cells harboring ATRX R781* in culture (PMID: 31551363).	31551363
ATRX S458*	high grade glioma	sensitive	Adavosertib	Preclinical - Patient cell culture	Actionable	In a preclinical study, Adavosertib (MK-1775) inhibited growth of patient-derived glioma cells harboring ATRX S458* in culture (PMID: 31551363).	31551363
FBXW7 del	Advanced Solid Tumor	sensitive	Adavosertib	Preclinical - Cell culture	Actionable	In a preclinical study, a cell line with knockout of FBXW7 demonstrated increased sensitivity to Adavosertib (MK-1775) compared to cells with wild-type FBXW7 in culture (PMID: 38032106).	38032106
FBXW7 R465H	cervical cancer	sensitive	Adavosertib	Preclinical - Cell culture	Actionable	In a preclinical study, a cervical cancer cell line harboring FBXW7 R465H demonstrated increased sensitivity to Adavosertib (MK-1775) treatment compared to a cell line with wild-type FBXW7 in culture (PMID: 38032106).	38032106
TP53 mutant	esophagus squamous cell carcinoma	predicted - sensitive	Adavosertib	Preclinical - Cell culture	Actionable	In a preclinical study, Adavosertib (MK-1775) treatment inhibited viability of TP53-mutant esophageal squamous cell carcinoma cells in culture (PMID: 32220892).	32220892
NRAS mutant	melanoma	sensitive	Adavosertib	Preclinical	Actionable	In a preclinical study, Adavosertib (MK-1775) showed efficacy in NRAS mutant melanoma and in mutant KRAS colorectal, pancreatic, and lung cancers (PMID: 24791855).	24791855
TP53 loss	Advanced Solid Tumor	sensitive	Adavosertib	Preclinical	Actionable	In a preclinical study, tumor cell lines carrying deficient TP53 were sensitized to DNA-damaging agents upon Adavosertib (MK-1775) administration (PMID: 19887545).	19887545

Showing 1 to 16 of 16 entries

Filter rows:

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Filter rows:

Showing 1 to 25 of 25 entries

Clinical Trial	Phase	Therapies	Title	Recruitment Status	Covered Countries	Other Countries
NCT02465060	Phase II	Erdafitinib Trametinib Crizotinib Sapanisertib Fexagratinib Dasatinib Osimertinib Palbociclib Capivasertib Larotrectinib Ulixertinib Nivolumab + Relatlimab Copanlisib Sunitinib Nivolumab Pertuzumab + Trastuzumab Ipatasertib Dabrafenib + Trametinib Binimetinib Adavosertib Afatinib Defactinib GSK2636771 Vismodegib Ado-trastuzumab emtansine Taselisib	Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)	Active, not recruiting	USA	2
NCT02659241	Phase I	Adavosertib	A Pilot Study of Induction Wee1 Inhibition in Ovarian Cancer	Active, not recruiting	USA	0
NCT03284385	Phase II	Adavosertib	Testing AZD1775 in Advanced Solid Tumors That Have a Mutation Called SETD2	Active, not recruiting	USA	0
NCT03385655	Phase II	Savolitinib Darolutamide Adavosertib	Prostate Cancer Biomarker Enrichment and Treatment Selection	Active, not recruiting	CAN	0
NCT03668340	Phase II	Adavosertib	AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma or Uterine Carcinosarcoma	Active, not recruiting	USA	0
NCT04460937	Phase I	Adavosertib	Testing the Addition of an Anti-cancer Drug, Adavosertib, to Radiation Therapy for Patients With Incurable Esophageal and Gastroesophageal Junction Cancers	Active, not recruiting	USA	0
NCT01357161	Phase II	Carboplatin Adavosertib Paclitaxel	A Study of MK-1775 in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone for Participants With Platinum-Sensitive Ovarian Tumors With the P53 Gene Mutation (MK-1775-004)	Completed		0
NCT01748825	Phase I	Adavosertib	MK-1775 for Advanced Solid Tumors	Completed	USA	0
NCT01922076	Phase I	Adavosertib	WEE1 Inhibitor MK-1775 and Local Radiation Therapy in Treating Younger Patients With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas	Completed	USA \| CAN	0
NCT02194829	Phase Ib/II	Paclitaxel Gemcitabine Adavosertib	Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Previously Untreated Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery	Completed	USA	0
NCT02341456	Phase I	Adavosertib Carboplatin Paclitaxel	Phase Ib Study AZD1775 in Combination With Carboplatin and Paclitaxel in Adult Asian Patients With Solid Tumours	Completed	AUS	2
NCT02508246	Phase I	Adavosertib Docetaxel Cisplatin	AZD1775, Docetaxel, and Cisplatin Before Surgery in Treating Patients With Borderline Resectable Stage III-IVB Squamous Cell Carcinoma of the Head and Neck	Completed	USA	0
NCT02511795	Phase I	Adavosertib Olaparib	AZD1775 Combined With Olaparib in Patients With Refractory Solid Tumors	Completed	USA \| CAN	0
NCT02513563	Phase II	Carboplatin + Paclitaxel Adavosertib	AZD1775 Plus Carboplatin-Paclitaxel in Squamous Cell Lung Cancer	Completed	USA	0
NCT02610075	Phase I	Adavosertib	Study to Determine MTD of AZD1775 Monotherapy in Patients With Locally Advanced or Metastatic Solid Tumours.	Completed	USA	0
NCT02666950	Phase II	Adavosertib Cytarabine	WEE1 Inhibitor AZD1775 With or Without Cytarabine in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome	Completed	USA	0
NCT03253679	Phase II	Adavosertib	WEE1 Inhibitor AZD1775 in Treating Patients With Advanced Refractory Solid Tumors With CCNE1 Amplification	Completed	USA	0
NCT03313557	Phase I	Adavosertib	AZD1775 Continued Access Study to Assess Safety and Tolerability for Patients Enrolled in AZD1775 Clinical Pharmacology Studies	Completed	USA \| NLD \| GBR \| FRA	0
NCT03333824	Phase I	Adavosertib	Effects of AZD1775 on the PK Substrates for CYP3A, CYP2C19, CYP1A2 and on QT Interval in Patients With Advanced Cancer	Completed	USA	0
NCT04590248	Phase II	Adavosertib	A Study of Adavosertib as Treatment for Uterine Serous Carcinoma (ADAGIO)	Completed	USA \| ITA \| FRA \| ESP \| CAN	0
NCT02087176	Phase II	Adavosertib Pegfilgrastim	A Placebo Controlled Study Comparing AZD1775+ Docetaxel Versus Placebo+Docetaxel to Treat Lung Cancer	Terminated	USA	0
NCT02087241	Phase II	Adavosertib Carboplatin + Pemetrexed Disodium	Ph II Trial of Carboplatin and Pemetrexed With or Without AZD1775 for Untreated Lung Cancer	Terminated	USA	0
NCT02196168	Phase II	Adavosertib Cisplatin	Cisplatin With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer	Terminated	CAN	0
NCT04949425	Phase I	Adavosertib	A Study to Assess the Safety and Tolerability of Adavosertib for Patients With Advanced Solid Tumours	Terminated	USA \| GBR	0
NCT02791919	Phase I	Adavosertib Cytarabine + Filgrastim + Fludarabine	Wee1 Kinase Inhibitor AZD1775 and Combination Chemotherapy in Treating Children, Adolescents and Young Adults With Relapsed or Refractory Acute Myeloid Leukemia	Withdrawn		0

Showing 1 to 25 of 25 entries

Filter rows:

Therapy Detail

Contact

Filtering

Sorting

Filtering

Sorting

Filtering

Sorting

Additional content available in CKB BOOST